Open AccessLow density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts
Author(s) -
Shamanna S. Iyengar
Publication year - 2016
Publication title -
journal of clinical and preventive cardiology
Language(s) - English
Resource type - Journals
eISSN - 2456-3366
pISSN - 2250-3528
DOI - 10.4103/2250-3528.192689
Subject(s) - pcsk9 , dyslipidemia , proprotein convertase , alirocumab , medicine , familial hypercholesterolemia , kexin , ezetimibe , evolocumab , primary prevention , atherosclerotic cardiovascular disease , disease , cholesterol , lipoprotein , ldl receptor , endocrinology , bioinformatics , biology , apolipoprotein a1
Low density lipoprotein cholesterol (LDL-C) is the target of lipid lowering therapy in subjects who have atherosclerotic cardiovascular disease (ASCVD) or who are at risk of developing it. There have been many debatable issues in this field. Should lifelong statins be prescribed for subjects at low risk of ASCVD in primary prevention? How low one can go in LDL-C lowering and is it safe? Should we "treat to target" or just administer high or moderate or low intensity statins based on the risk category? What is the role of nonstatin drugs in lipid lowering therapy? Are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors) going to be the game changers? There is an abundance of literature looking at these matters. Statins continue to be the first choice in dyslipidemia management. PCSK9 inhibitors would be a welcome addition to the armamentarium or an attractive alternative in certain situations